Literature DB >> 7142749

Evaluation of a cold-recombinant influenza virus vaccine in ferrets.

H F Maassab, A P Kendal, G D Abrams, A S Monto.   

Abstract

Cold-recombinant strains of influenza virus were derived at 25 C using an attenuated cold-adapted (ca) and temperature-sensitive (ts) A/Ann Arbor/6/60 (H2N2) strain and wild-type (wt) strains of epidemic relevance. The cold recombinants were characterized in ferrets in terms of clinical manifestations, viral titers, and histopathologic lesions in turbinates and lungs. The data in ferrets showed that cold recombinants with six genes derived from the ca "master" strain and the two surface antigens of the wt parent strain were predictably attenuated and genetically stable. Attenuation of recombinants with an additional gene derived from the wt parent was less predictable. Recombinants possessing the nonstructural gene of the wt parent showed some reactogenicity at high doses, whereas cold recombinants with RNA 2 from the wt parent did not. A recombinant strain possessing RNA 7 of the wt parent showed reversion to the ts+ phenotype but remained attenuated. Similar results were obtained from testing the recombinants in humans.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7142749     DOI: 10.1093/infdis/146.6.780

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.

Authors:  M H Snyder; R F Betts; D DeBorde; E L Tierney; M L Clements; D Herrington; S D Sears; R Dolin; H F Maassab; B R Murphy
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

2.  Cold-adapted reassortants of influenza A virus: pathogenicity of A/Ann Arbor/6/60 X A/Alaska/6/77 reassortant viruses in vivo and in vitro.

Authors:  A W Heath; H F Maassab; T Odagiri; D C DeBorde; C W Potter
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

3.  Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site.

Authors:  Tatiana Kotomina; Daniil Korenkov; Victoria Matyushenko; Polina Prokopenko; Larisa Rudenko; Irina Isakova-Sivak
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

4.  Genetically engineered live attenuated influenza A virus vaccine candidates.

Authors:  N T Parkin; P Chiu; K Coelingh
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  MicroRNA-Based Attenuation of Influenza Virus across Susceptible Hosts.

Authors:  Louisa E Sjaastad; Jessica K Fiege; Barbara M Waring; Elizabeth J Fay; Ismarc Reyes; Branden Moriarity; Ryan A Langlois
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

6.  Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus.

Authors:  M H Snyder; M L Clements; D De Borde; H F Maassab; B R Murphy
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

7.  Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1), in Japanese adult volunteers.

Authors:  N Yamane; Y Nakamura; M Yuki; T Odagiri; N Ishida
Journal:  J Hyg (Lond)       Date:  1984-04

8.  Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans.

Authors:  J S Youngner; J J Treanor; R F Betts; P Whitaker-Dowling
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

9.  Molecular and biological changes in the cold-adapted "master strain" A/AA/6/60 (H2N2) influenza virus.

Authors:  M L Herlocher; H F Maassab; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates.

Authors:  Haichen Song; Gloria Ramirez Nieto; Daniel R Perez
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.